Improved Insulin Sensitivity and Body Fat Distribution in HIV‐Infected Patients Treated With Rosiglitazone: A Pilot Study

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2002-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.QAI.0000028380.12927.4APMID 12394794
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucose Disorders Associated with HIV and its Drug Therapy

  2001cited by this paper
• Metabolic complications associated with antiretroviral therapy.

  2001cited by this paper
• Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

  2001cited by this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cited by this paper
• The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.

  2001cited by this paper
• Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.

  2001cited by this paper
• HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

  2001cited by this paper
• Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.

  2001cited by this paper
• Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy

  2000cited by this paper
• Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study

  2000cited by this paper
• Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.

  2000cited by this paper
• Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes

  2000cited by this paper
• Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection

  2000cited by this paper
• PPAR gamma and the treatment of insulin resistance.

  2000cited by this paper
• Metabolic Disorders Among HIV‐Infected Patients Treated With Protease Inhibitors: A Review

  2000cited by this paper
• Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

  1999cited by this paper
• Promising new approaches.

  1999cited by this paper
• Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study--Dual-Energy X-ray Absorptiometry and Body Composition Working Group.

  1999cited by this paper
• Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

  1999cited by this paper
• Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.

  1999cited by this paper
• Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

  1999cited by this paper
• Effect of troglitazone on body fat distribution in type 2 diabetic patients.

  1999cited by this paper
• Transcriptional activation of adipogenesis.

  1999cited by this paper
• Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus

  1999cited by this paper
• Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women.

  1999cited by this paper
• Cellular mechanisms of insulin resistance in humans.

  1999cited by this paper
• "Buffalo hump" in men with HIV-1 infection.

  1998cited by this paper
• Visceral abdominal-fat accumulation associated with use of indinavir.

  1998cited by this paper
• Depot-Specific Differences in Adipose Tissue Gene Expression in Lean and Obese Subjects

  1998cited by this paper
• Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus.

  1998cited by this paper
• Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus

  1998cited by this paper
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

  1998cited by this paper
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

  1998cited by this paper
• Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.

  1997cited by this paper
• PATHOGENESIS OF THE INSULIN RESISTANCE SYNDROME (SYNDROME X)

  1997cited by this paper
• Transient State of NIDDM in a Patient With AIDS

  1993cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper
• Abdominal fat assessed by computed tomography: sex difference in distribution.

  1983cited by this paper
• Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man.

  1981cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper

• Current status and perspectives in the treatment of facial lipoatrophy in HIV-positive patients in 2024.

  2024cites this paper
• Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update

  2018cites this paper
• Gelidium elegans Regulates Blood Glucose Homeostasis in ICR Mice

  2017cites this paper
• The Effect of Recombinant Human Growth Hormone with or without Rosiglitazone on Hepatic Fat Content in HIV-1-Infected Individuals: A Randomized Clinical Trial

  2016cites this paper
• Diabetes and HIV.

  2014cites this paper
• Chromium Therapy for Insulin Resistance Associated with HIV-Disease.

  2013cites this paper
• A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial

  2013cites this paper
• Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial

  2013cites this paper
• Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome.

  2013cites this paper
• HIV medications: an update and review of metabolic complications.

  2012cites this paper
• Metabolic Complications Associated with HIV Protease Inhibitor Therapy

  2012cites this paper
• Lipodystrophy: pathophysiology and advances in treatment

  2011cites this paper
• Insulin resistance in treated HIV infection.

  2011cites this paper
• Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance

  2011cites this paper
• Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.

  2011cites this paper
• Carotid Intima Media Thickness, Inflammatory Markers, and Endothelial Activation Markers in HIV Patients with Lipoatrophy Increased at 48 Weeks Regardless of Use of Rosiglitazone or Placebo

  2011cites this paper
• Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study.

  2011cites this paper
• A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy

  2010cites this paper
• The HIV-1/HAART associated metabolic syndrome - novel adipokines, molecular associations and therapeutic implications.

  2010cites this paper
• Comparison of Poly-L-lactic Acid and Calcium Hydroxylapatite for Treating Human Immunodeficiency Virus – Associated Facial Lipoatrophy

  2010cites this paper
• The Effect of Rosiglitazone on Insulin Sensitivity, Beta Cell Function, Bone Mineral Density, and Body Composition in HIV-positive Patients on Highly-active Antiretroviral Therapy (HAART)

  2009cites this paper
• A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.

  2009cites this paper
• Prevalence of Dyslipidemia in HIV Patients and HIV Patients receiving Highly Active Anti - Retroviral Therapy: Cross Sectional Comparative study

  2009cites this paper
• Management of Morphologic Changes Associated With Antiretroviral Use in HIV-Infected Patients

  2008cites this paper
• Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease.

  2008cites this paper
• Adiponectin in glucose metabolism

  2008cites this paper
• Clinical aspects of toxicity in antiretroviral therapy

  2008cites this paper
• A rosiglitazone-induced increase in plasma adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy 8

  2008cites this paper
• UvA-DARE ( Digital Academic Repository ) Adiponectin in glucose metabolism

  2008cites this paper
• Antiretroviral therapy and the human immunodeficiency virus – improved survival but at what cost?

  2008cites this paper
• Treatment options for lipodystrophy in HIV-positive patients

  2008cites this paper
• The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

  2008cites this paper
• Treatment of Altered Body Composition in HIV-Associated Lipodystrophy: Comparison of Rosiglitazone, Pravastatin, and Recombinant Human Growth Hormone

  2008cites this paper
• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

  2008cites this paper
• Pathogenesis and management of lipoatrophy

  2008cites this paper
• Plasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes

  2007cites this paper
• Increased incidence of mucosal candidiasis after HAART initiation: a benign form of immune reconstitution disease?

  2007cites this paper
• Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients

  2007cites this paper
• Use of metabolic drugs and fish oil in HIV‐positive patients with metabolic complications and associations with dyslipidaemia and treatment targets

  2007cites this paper
• Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12-Week Induction and 24-Week Maintenance Therapy

  2007cites this paper
• Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial.

  2007cites this paper
• Effect of Rosiglitazone on Visfatin and Retinol‐Binding Protein‐4 Plasma Concentrations in HIV‐Positive Patients

  2007cites this paper
• The role of adipokines in relation to HIV lipodystrophy

  2007cites this paper
• Surgical Algorithm for Management of HIV Lipodystrophy

  2007cites this paper
• Thiazolidinediones in dermatology

  2007cites this paper
• Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy

  2007cites this paper
• Use of thiazolidinediones in HIV-infected patients: what have we learned?

  2007cites this paper
• Insulin resistance and HIV infection: a review

  2007cites this paper
• The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients

  2007cites this paper
• Correlates of prevalent hypertension in a large cohort of HIV-infected women: Women's Interagency HIV Study

  2007cites this paper
• Retention in care: a challenge to survival with HIV infection.

  2007cites this paper
• Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio

  2007cites this paper
• Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.

  2006cites this paper
• Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

  2006cites this paper
• Evaluation of Safety and Efficacy of Rosiglitazone in the Treatment of HIV-Associated Lipodystrophy Syndrome

  2006cites this paper
• HIV-associated lipodystrophy syndrome.

  2006cites this paper
• Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.

  2006cites this paper
• Abnormal Glucose Regulation and Treatment Strategies for Insulin Resistance HIV-Infected Patients

  2006cites this paper
• Metabolic complications of HIV therapy.

  2006cites this paper
• [Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection].

  2006cites this paper
• COPING WITH HIV AND ANTIRETROVIRAL THERAPY —

  2006cites this paper
• Cardiovascular risk associated with antiretroviral therapy in HIV-infected patients

  2006cites this paper
• Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

  2005cites this paper
• HIV and liver diseases: recent clinical advances.

  2005cites this paper
• Cardiovascular disease in HIV-positive patients.

  2005cites this paper
• Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.

  2005cites this paper
• HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.

  2005cites this paper
• Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.

  2005cites this paper
• Current perspectives on HIV-associated lipodystrophy syndrome.

  2005cites this paper
• Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.

  2005cites this paper
• Interventions for managing antiretroviral therapy-associated lipoatrophy

  2005cites this paper
• Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.

  2005cites this paper
• HIV facial lipoatrophy: causes and treatment options.

  2005cites this paper
• Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy

  2005cites this paper
• Does GB virus C protect against HIV disease progression?

  2005cites this paper
• Protease Inhibitor-Induced Diabetic Complications

  2005cites this paper
• The effects of HIV protease inhibitors on carbohydrate and lipid metabolism

  2005cites this paper
• Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

  2005cites this paper
• Glitazones and the management of insulin resistance: what they do and how might they be used.

  2004cites this paper
• Treatment of metabolic syndrome

  2004cites this paper
• Pathophysiology of the HIV-Associated Lipodystrophy Syndrome

  2004cites this paper
• Benfluorex As a Therapeutic Option for Insulin Resistance in HIV Lipodystrophy Syndrome

  2004cites this paper
• Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy.

  2004cites this paper
• TrialMen With Lipodystrophy : A Randomized Controlled Growth Hormone – Releasing Hormone in HIV-Infected

  2004cites this paper
• Pharmacologic Therapy for HIV-Associated Lipodystrophy

  2004cites this paper
• Ai1812co 1741..1749

  2004cites this paper
• Management of Dyslipidaemia in HIV-Infected Patients Receiving Antiretroviral Therapy

  2004cites this paper
• Managing HIV lipoatrophy.

  2004cites this paper
• Update on HIV Lipodystrophy

  2004cites this paper
• Metabolic complications of HIV therapy in children

  2004cites this paper
• [Metabolic abnormalities in patients with HIV infection].

  2004cites this paper
• Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy.

  2004cites this paper
• HIV lipodystrophy syndrome: a primer.

  2004cites this paper
• To Butterfly or To Needle: The Specimen Testing Question

  2004cites this paper
• Acetyl‐l‐carnitine for the Treatment of HIV Lipoatrophy

  2004cites this paper
• Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients.

  2004cites this paper
• Insulin Resistance and Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral Therapy

  2004cites this paper
• Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.

  2004cites this paper
• Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients

  2004cites this paper
• Low-Carbohydrate Diets

  2004cites this paper